Introduction
Cancer and cardiovascular (CV) disease are the most common causes of death in Europe. 1 Increasing numbers of cancer patients are surviving free of recurrence or living with the disease owing to major advances in oncology treatments; an estimated 2.5 million people are living with cancer in the UK. 2 Improvements in cardiac and cancer treatments combined with an ageing population have resulted in cancer being diagnosed in an been developed with the purposes of (i) identifying patients at an increased baseline CV risk before commencing cancer treatment; (ii) minimising their risk using primary prevention strategies; (iii) diagnosing and treating myocardial toxicity during or after cancer treatment; (iv) supporting the patient through their cancer treatment regime with a personalised surveillance programme; and (v) appropriate medium and long-term follow-up for patients with CV disease attributed to cancer therapies.
As cardio-oncology services are relatively new, there has been limited description of their activity and results. Here we report the 5-year consecutive experience of a cardio-oncology service in the UK. We hypothesised that a personalised approach to evaluation and optimisation of patients at high baseline risk or with established left ventricular systolic dysfunction (LVSD) would limit cancer treatment interruption and improve outcome.
Methods
The cardio-oncology clinic is based at the Royal Brompton Hospital, London, UK. The service is staffed by three consultant cardiologists (A.R.L., S.R. and R.K.S.), a senior clinical fellow in cardio-oncology (N.P. and J.C.) and a senior clinical nurse specialist (Band 8) (V.C.), supported by specialist cardiac imaging with advanced echocardiography (R.K.) and CV magnetic resonance (CMR) (J.B.). The service operates an initial one-stop day case service model in order to expedite assessment of CV status and provide a rapid opinion to referrers. After establishment, the service was publicised by creation of a service website (http://www.rbht.nhs.uk/patients/condition/cardiooncology), dissemination of referral documents to local centres and presentations at referring oncology hospitals, oncology meetings and cardio-oncology conferences. Table 1 indicates common reasons for referral to the service and our approach at baseline and follow-up. We implemented a protocol where all new referrals attend for a baseline clinical assessment. The latter incorporates blood tests, including cardiac biomarkers, resting 12-lead electrocardiogram (ECG) and a resting two-dimensional transthoracic echocardiography (2D TTE) based on the British Society of Echocardiography recommendations in all patients. 8 Stress echocardiography (to assess for ischaemia and/or contractile reserve) and CMR were performed in selected patients. CMR protocols applied to measure left and right ventricular function, plus T2-STIR and late gadolinium enhancement (LGE) in order to detect additional markers of clinical toxicity (i.e. fibrosis), or to assess cardiac masses and their perfusion. TTE was used for serial comparison at follow-up using the same echocardiography model and vendor.
We defined left ventricular dysfunction using our new Royal Brompton Hospital myocardial toxicity definition ( Table 2 ). This was developed as a practical clinical tool to incorporate early biochemical and functional changes and to define a severity gradient from least severe (Group 1) to the most severe (Group 6). Our classification is adapted from the Cardiac Review and Evaluation Committee of Trastuzumab-Associated Cardiotoxicity (CREC) criteria but includes more clinically relevant variables. 7 Elevation of biomarker levels was defined as any value above the laboratory's normal reference range [brain natriuretic peptide (BNP) >20 ng/L and troponin I > 20 ng/L]. BNP was measured during follow-up of patients deemed at highest risk of deterioration based on clinical opinion.
After multidisciplinary team discussion and consultation, patients requiring current cancer treatment were classified as either (i) fit, (ii) at too high risk, or (iii) requiring further CV optimisation to continue their cancer therapy based on a case by case decision depending on severity of cardiac disease (pre-existing cardiac disease, co-morbidities and cancer drug-related cardiotoxicity) and severity of the cancer-stage, receptor status and treatment options (including non-cardiotoxic treatments). Close surveillance in higher risk patients at baseline or those with established cardiotoxicity was recommended in those with a requirement for ongoing cancer treatment ( Table 2) . Follow-up consultations with TTE to assess left ventricular ejection fraction (LVEF) and global longitudinal strain (GLS) (where indicated) were personalised for each patient depending on current oncology treatment, LVEF, symptoms, cancer stage and response. In general, first follow-up consultations were offered at 3-6 months following completion of cancer treatment for low-risk patients, at 2-4 weeks for those at high baseline risk or where oncology treatment is ongoing but interrupted for cardiotoxicity to enable initiation and rapid up-titration of guideline-based heart failure treatment. The monitoring of higher risk patients occurred at every 1-3 treatment cycles depending upon the severity of cardiotoxicity, response to cardiac treatment and the dose and duration of planned further oncology treatment. When appropriate, patients were prescribed statins and antiplatelet agents, recommended moderate physical activity and lifestyle changes, as well as a consultation with our clinical nurse specialist.
We specifically analysed three subgroups of patients: (i) patients referred to our service due to an exceedingly high CV risk, (ii) patients that developed any myocardial toxicity as per our definitions (Groups 1-6), and (iii) those with significant LVEF reduction (Groups 5 and 6).
The primary outcome measures were rates of cancer treatment at follow-up, as well as the overall and CV mortality. Since many patients were expected deaths due to cancer progression without post-mortems, we defined the cause of mortality as the most likely cause as per patient clinical status at the last consultation. CV death was classified as worsening congestive heart failure (CHF) at last consultation and cancer-related death where progressive metastatic disease was present. When patients' condition was stable from both a CV and oncological perspective, the cause of death was labelled as unexpected. The secondary CV outcome measures in those with LVSD were a change in New York Heart Association (NYHA) status and LVEF at follow-up, as well as successful up-titration of guideline-based CHF treatments, defined as a numerical increase in equivalent guideline-based therapies for LVSD.
Data were collected prospectively and analysed with the SPSS statistical package (SPSS Inc., Chicago, IL, USA). Normally distributed data are presented as mean ±standard deviation. Non-normally distributed data are presented as medians with ranges or interquartile range (IQR). Comparisons were performed with Student's t-test for normally distributed variables; Chi-square for proportions and Mood's median test for non-normally distributed variables. A P-value of <0.05 was considered statistically significant.
Results

Patient baseline characteristics
A total of 535 patients (55.8% females) were referred between 1 February 2011 and 1 February 2016. Baseline characteristics of the patients are listed in Table 3 . Pre-existing CV risk factors were common, reflecting referral patterns to the service. Patients with 31 types of cancer were referred; 171 patients (31.9%) had metastatic cancer ( Figure 1A and 1B) . Eighteen patients (3.4%) had evidence of primary or metastatic cardiac involvement, the majority of which were sarcomas. Fifty-four patients (10.1%) had a second malignancy; of this cohort 38 patients (70.4%) had received prior chemotherapy. We identified 128 patients (23.9%) with evidence of LVSD from any cause as per our classification (Groups 5 and 6). Patients in this group were more likely to be younger, with a lower burden of CV risk factors and significantly higher previous exposure to chemotherapy and radiotherapy (P < 0.001). Amongst routine cardiac biomarkers, the frequency of elevated serum BNP levels at referral did not differ between groups but there was a statistical difference in the rates of elevated serum cardiac troponin I.
Cardiac structural abnormalities were seen in 22% of patients with normal LVEF-including valvular heart disease, pericardial effusions and/or cardiac masses. LGE was detected in 100 of all patients who underwent CMR (22.8%), without significant differences between patients with and without LVSD as per our classification ( Table 3) . Of the patients who had positive LGE, 22 (22%) had prior coronary artery disease and 40 (40%) had hypertension. Quantification of LVEF by CMR and TTE was strongly positively correlated (r = 0.796, P < 0.01). Patient flow through the clinic and rates of myocardial toxicity by referral stream are summarized in Figure 1C and or CHF during or after cancer treatment (n = 134, 25.0%). Of the 535 patients, 347 (64.9%) had received any prior medical cancer therapy and 139 patients (25.9%) had prior radiotherapy, of which only 37 (6.9%) received potentially cardiotoxic radiotherapy to the left breast, left chest, or mediastinum.
Patients at high baseline risk before cancer treatment
A total of 238 patients (44.4%) were deemed at high baseline risk by their oncology team and were referred for assessment prior to receiving further cancer surgery (n = 131, 55%), or potentially cardiotoxic first-line cancer therapy (n = 107, 45%). Median LVEF was 61% (IQR 55-66%) but there was a high prevalence of CV risk factors in this group including hypertension (42%), pre-existing CHF (10%) and established coronary artery disease (18%) underlying the clinical rationale for their referral. In these patients, we detected an abnormal LVEF (<55%) in 18% and a significant structural abnormality in a further 18% (including valvular heart disease, previous myocardial infarction, hypertrophic cardiomyopathy or pericardial effusion). We performed stress echocardiography in 157 of these 238 referred patients (66%) and inducible ischaemia was identified in only 2%, who were subsequently referred for coronary angiography/optimisation of medical therapy. After our initial assessment, 110 patients (46.0%) were treated with beta-blockers, 77 patients (32.3%) with angiotensin-converting enzyme inhibitors, and 34 patients (14.2%) with angiotensin II receptor blockers. At this point, 86% of patients were deemed fit for further cancer treatment, only 4% of patients were deemed too high risk, and 10% of patients required optimisation. Finally, of the latter patients, two-thirds successfully received their indicated cancer treatment after optimisation, resulting in a final 92.4% cancer treatment rate ( Figure 3A) .
Rates of myocardial toxicity by the Royal Brompton Hospital definition
We concentrated our analysis to the most recognized cardiotoxic agents-anthracyclines, anti-HER2 agents, vascular endothelial growth factor tirosine kinase inhibitors (TKIs) and immune therapies, which are detailed in commonly used cardiotoxic agents; the highest rates of toxicity were witnessed in the patients receiving immunotherapy (77.2%, n = 17), but with relatively lower rates of reduction of LVEF (36.3%, n = 8), compared to other agents. Reductions in LVEF were more common with the use of anthracyclines and anti-HER2 agents (53.8% and 49.2%, respectively). The rates of toxicity were lower with the use of anti-HER2 agents and TKI, mainly due to a lower rate of symptomatic heart failure (22.2% and 19.7%, respectively).
Rates of cardiovascular toxicity in TKIs were significant, occurring in 62.1% of patients (n = 41), driven primarily by hypertension, with direct myocardial toxicity reflected mainly by a combination of symptomatic and asymptomatic reduction in LVEF. ECGs from 30 patients treated with TKIs were available for analysis. The median QTc was 439 ms (range 383-520 ms), of whom 12 patients had a QTc >450 ms. These proportions reflect the referred population which is influenced by development of new cardiac symptoms on treatment and cardiac surveillance (anti-HER2 therapies). Table 5 focuses on the patients with myocardial toxicity as per our criteria who required ongoing medical cancer treatment irrespective of referral source. Across all the groups, rates of optimisation of CV agents after our first assessment was high (74.3%, n = 124), with a progressive stepwise increase from Groups 1-6. The majority of patients were deemed CV fit to continue with their cancer therapies (93.4%, n = 156) including all patients in Groups 1-4. Despite this, final cancer treatment completion rate was far lower due to oncological reasons (65.3%, n = 109) and survival at follow-up was poor in general (59.9%, n = 100), and worst in Group 1 of myocardial toxicity. CV and unexpected mortality rates were generally low across all groups (20.9%, n = 14).
Management and outcomes of patients with myocardial toxicity requiring ongoing cancer treatment
Diagnosis, management and outcomes in the subgroup with left ventricular dysfunction
A total of 128 patients had evidence of LVSD from any cause ( suitable for initiation or continuation of cancer therapy; after cardiac optimisation, this figure rose to 89% of patients ( Figure 3B) . As a result, 67% of patients with LVSD were able to complete their cancer drug regimens; 22% were deemed fit for drug therapy but did not ultimately receive further treatment after discussion with the oncology team; only 11% were considered too high risk from a CV perspective. After the first appointment, 113 patients (88%) had their CHF medications optimised as per current guidelines. Including follow-up, 120 patients (94%) had an up-titration of their cardiac medications by our service. Table 6 presents the rates of most frequently used CV agents after the first appointment and at follow-up. Our follow-up rate was 88%, with a median follow-up of 360 days (IQR 84-735 days). Median LVEF on assessment was 45% (IQR 0.39-0.50), which rose to 53% (IQR 0.48-0.60) at follow-up (P < 0.001). Overall, patients were less symptomatic at follow-up, with NYHA class III-IV in 27 patients (22%) on first assessment and 11 patients (10%) at follow-up (P = 0.01). Mortality at follow-up was lowest in those who were deemed fit for continuation of cancer treatment (16/66; 24.2%), higher in those CV suitable but ultimately did not receive cancer treatment (11/22; 50.0%) and highest in those who were deemed too high risk (8/10; 80%) (P < 0.01). In total, 44 patients with LVSD (34.4%) died at follow-up, with the cause of death being CV or unexpected in 10 patients (22.7%). This death rate was comparable to that in patients without LVSD (n = 125, 30.7%, of which the cause of death 
Service activity and patient feedback
For the period when patient feedback was available (2012-2016), clinic activity increased from 105 (in 2012) to 179 patients/year (in 2016) with a significant increase in the average number of new day case assessment patients seen in our weekly clinic (2.3 ±1.08 vs. 3.64 ±1.12 patients/day; P < 0.001). For the same period, median waiting time was 12 days (IQR [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . The degree of satisfaction for the overall day case experience (1 = extremely dissatisfied; 10 = extremely satisfied) was high with an average rating of 9.42.
Discussion
The main finding of this 5-year real-world experience of the first purpose-designed cardio-oncology service in the UK is that implementation of standardised protocols of care can achieve optimisation of the CV status of patients at high baseline risk or with established myocardial toxicity, leading to high levels of cancer treatment. There is a signal that, in the highest risk patients with . The rising prevalence of CV risk factors and cardiotoxicity in cancer has led to an increasing demand for cardio-oncology services. Small scale reports, 9 society guidelines 10,11 and more recently a position report from the European Society of Cardiology (ESC) 3 have proposed surveillance and treatment strategies for patients at high baseline risk and with established myocardial toxicity. One of the principal aims of a cardio-oncology service is to improve LVEF and functional class which may then render patients more suitable for ongoing cancer therapies, which is particularly important since there is emerging evidence that interruptions in cancer treatment are associated with a higher incidence of cancer recurrence.
12 On the other hand, it is also conceivable, since mortality for many cancers remains high, that optimisation of LVEF and functional class may not confer significant benefit on prognosis. Certainly, in our cohort, CV and unexpected mortality rates were low, reflecting the poor prognosis of cancer in these highly selected group of patients. There remains limited data pertaining to the delivery and outcomes of cardio-oncology services, particularly with respect to how they may impact cancer treatment and survival.
Previous randomised controlled trial data have shown that institution of CHF treatments at baseline in high-risk patients exposed to cardiotoxic treatments can reduce symptomatic CHF and LVEF reduction but with an unclear effect on cancer treatment.
13 -16 Our study shows that with CV optimisation of this group of patients, we were able to optimise and deem fit from a CV point of view the majority of patients referred before continuing cancer treatment, who may not have experienced delays or had significantly lower treatment rates. We developed an assessment tool for referring hospitals to identify patients at high baseline risk and we follow the current ESC guidelines for non-cardiac surgery as a foundation, but with an individualised approach to the patient (e.g. for neo-adjuvant chemotherapy with cardiotoxic drugs). 17 The patients in our series had a significant burden of CV risk factors but the low rates of ischaemia observed are likely to reflect possible separate referral pathways for patients with ischaemic symptoms, e.g. direct to interventional cardiologists.
The most commonly used definition for myocardial toxicity is the CREC [low LVEF (≤50%) or significant drop of LVEF (>10%) below 55% during chemotherapy with or without symptoms], and rates of myocardial toxicity in clinical trials have been less than 5%. 18 Rates of myocardial toxicity in clinical trials have varied; this reflects the baseline risk of recruited patients, short durations of follow-up and variability of definitions of myocardial toxicity for which there is no clear consensus. incorporate early abnormalities since they may predispose to future susceptibility, identify higher risk patients that could benefit from pre-emptive therapy and since it is more applicable to current clinical practice. Using this classification, the rate of established myocardial toxicity in our series was significantly higher than in clinical trials and previously reported literature. 18 The increased rates of myocardial toxicity observed in our series reflects a selected population of higher risk and symptomatic patients, who may have been excluded from clinical trials owing to high rates of prevalent CV disease, as well as the inclusion of biochemical and sub-clinical markers of dysfunction. Consistent with other registries, 21 rates of asymptomatic reductions in LVEF were high reflecting appropriate referral of those with high baseline risk driven by pre-existing CV disease and those who had cardiotoxicity detected during standard surveillance protocols in the oncology services, e.g. LVSD in patients receiving trastuzumab for HER2+ breast cancer. 19, 22 The long-term clinical significance of de novo asymptomatic left ventricular diastolic dysfunction or biochemical or functional cardiotoxicity with a preserved LVEF (>55%) is currently unclear, but as these findings are an objective marker of myocardial toxicity, they have been included in our analysis. For example, BNP elevation in the setting of normal LVEF may reflect increased myocardial wall strain directly related to the cancer or treatment. 23, 24 Indeed, in our study, despite high levels of CV fitness for therapy and similar rates of cancer treatment, the cohort of patients with isolated biochemical myocardial toxicity (Group 1) experienced the highest mortality amongst all. This may indicate that subtle increases in BNP are a signal for an early but clinically significant process of myocardial toxicity or perhaps may reflect more advanced systemic disease. This could also explain why BNP values did not differ between the subgroups of patients or change over time. Future studies evaluating the significance of these findings, effect on outcome and rationale for pre-emptive treatment are required.
We specifically focused on patients with reduced LVEF, as this has been an exclusion criteria in most clinical trials involving potentially myocardial toxic drugs. A previous small retrospective study suggested that for patients with established myocardial toxicity, a cardiology consultation was associated with up-titration of heart failure medications and improved survival. 25 Our protocolised model of care led to improvements in LVEF and NYHA class in accordance with previous studies 26, 27 but also, importantly, a high rate of continuation of cancer therapies. This subset of patients was younger and with fewer co-morbidities than patients without LVSD, but with a higher rate of oncological treatments.
Although the numbers were small, we provide preliminary evidence that being deemed CV fit and continuing cancer therapy specifically in patients with LVSD may reduce mortality. After evaluation in our service, all patients without LVSD were deemed CV fit but cancer treatment completion rates were significantly lower due to oncological reasons. Mortality rates were generally comparable across all groups of myocardial toxicity and worst in Group highlights that the decision to continue cancer treatment is complex and emphasises the importance of a multidisciplinary process. We could also, however, hypothesise that with appropriate CHF treatment and improved LVEF in patients with LVSD particularly, we rendered patients more able to complete their oncological treatment-hence improving outcome. A prospective, larger scale comparison of cardio-oncology services with current standard of care is required to clarify this issue. We operate a one-stop day case model in order to provide a rapid opinion to the referring unit thereby minimising interruptions of care and to improve the patient experience, which was confirmed by the excellent feedback we received. This patient group has, by definition, received a double blow, firstly that of a cancer diagnosis, which itself is challenging, but then compounded by actual or threatened heart disease. The latter discovery can be psychologically challenging for patients, but the support gained from a team with experience in this specific area and with treatments to offer had major positive impact.
Study limitations
This descriptive analysis represents a clinical experience from a single centre. Although this allows a uniform protocol for assessment and treatment, it is therefore susceptible to a referral bias based on the expertise of our main referral centre. We recognise that patients with LVSD may have been younger due to a referral bias from breast cancer and sarcoma services and that the higher rates of cardiotoxicity reported are likely to represent a higher risk case mix referred to our service. Certain malignancies were not commonly seen in this service, for example acute leukaemias, but patients with 33 types of cancer were BNP, brain natriuretic peptide; CAD, coronary artery disease; CHF, congestive heart failure; CMR, cardiovascular magnetic resonance; HFpEF, heart failure with preserved ejection fraction; LGE, late gadolinium enhancement; LVEF, left ventricular ejection fraction; LVSD, left ventricular systolic dysfunction; N/A, not applicable; SD, standard deviation; TKI, tirosine kinase inhibitor. Values are given as number (%). CV, cardiovascular.
represented, and it is likely that the results are generalisable. We also acknowledge that there was no control group of patients at high baseline risk who did not receive optimisation, but since without optimisation their treatment rates would have certainly been much lower, we feel the high rates of cancer treatment . . . . . . . . . . . . . . . continuation remain relevant. Finally, similarly, a comparator group of patients with LVSD not receiving cardiac treatment was not included due to the specific nature of our service but future studies should consider comparing outcomes of cardio-oncology services with standard care. 
Conclusions
In our descriptive analysis reporting the 5-year activity of a UK based cardio-oncology service, we observed a higher rate of prior CV disease and myocardial toxicity than that previously reported in the literature. Prompt evaluation of CV risk with optimisation led to improvements in LVEF and NYHA class and high rates of cancer treatment continuation. Conflict of interest: none declared.
